Personalis, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
Personalis develops advanced cancer genomic tests, analytics, sequencing, and data-analysis services for pharmaceutical, diagnostics, government, academic, and other customers. The company is expanding into clinical cancer diagnostics, including NeXT Dx and NeXT Personal Dx, while continuing population-sequencing work for the U.S. Department of Veterans Affairs Million Veteran Program. The filing covers the three months ended March 31, 2024; all financial amounts below are in millions unless stated otherwise.
Financial Performance and Liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $19.5 | $18.9 | 4% |
| Gross profit | $5.5 | $4.7 | 17% |
| Gross margin | 28.1% | 25.1% | +3.0 percentage points |
| Loss from operations | $(18.9) | $(29.8) | Improved $10.9 |
| Operating margin | (96.7%) | (158.1%) | Improved |
| Net loss | $(13.0) | $(28.7) | Improved $15.7 |
| Net loss per share | $(0.26) | $(0.61) | Improved |
| Cash used in operations | $(20.4) | $(15.7) | Use increased $4.7 |
- Revenue mix: pharma tests and services were $9.8 million, up 55%; enterprise sales were $8.0 million, down 16%; population sequencing was $1.5 million, down 50%; and other revenue was $0.2 million.
- Natera represented 41% of revenue and Moderna 24%. The top five customers represented 83% of revenue, highlighting substantial concentration.
- Cash and cash equivalents were $44.0 million and short-term investments were $51.4 million at March 31, 2024, for total cash and investments of $95.4 million, down from $114.2 million at December 31, 2023.
- Working capital was $89.1 million, compared with $99.5 million at year-end 2023.
- Total debt was $2.6 million, including $1.7 million current and $0.9 million long-term. Lease liabilities were $45.2 million, with $76.6 million of undiscounted future operating lease payments.
- Investing activities provided $6.3 million, primarily from net maturities of short-term investments. Financing activities provided $1.1 million, including $1.4 million of net ATM equity proceeds, partly offset by $0.3 million of loan repayments.
Material Changes Versus the Prior Comparable Period
- Total costs and expenses declined 21% to $38.4 million. Research and development expense fell 23% to $12.8 million and selling, general and administrative expense fell 18% to $11.6 million, primarily due to 2023 workforce reductions.
- No restructuring charge was recorded in Q1 2024, compared with $3.9 million in Q1 2023. The second workforce reduction, affecting approximately 60 employees, was completed during Q1 2024, and the company does not expect material additional related costs.
- Other income was $4.6 million, principally from a $4.8 million noncash gain arising from the decrease in the fair value of Tempus warrant liabilities. This materially reduced the reported net loss but does not represent operating cash generation.
- Operating cash use increased because annual bonuses were paid in Q1 2024 and the company did not receive a comparable customer deposit from Moderna. Higher customer collections partly offset these items.
- Enterprise revenue declined despite Natera sample volumes increasing by more than 20%, because of lower selling prices. Personalis launched a reduced-cost exome offering for Natera and expects total Natera revenue to decline from comparable 2023 periods, although minimum volume commitments extend through year-end 2024.
- Population-sequencing revenue declined because fewer VA MVP samples were processed. The company had $5.9 million of remaining VA MVP task orders at the end of the reporting period, expected to be recognized over the following two to three quarters.
Guidance, Outlook, Commentary, Risks, and Unusual Items
- Management stated that existing cash, cash equivalents, short-term investments, and expected operating cash flows should fund capital and operating needs for at least the next 12 months, but noted that this conclusion depends on assumptions that may prove inaccurate.
- The company expects operating expenditures to decrease in 2024 following workforce reductions, capital expenditures of approximately $1 million in 2024, and capital expenditures of $4 million to $6 million in each of 2025 and 2026.
- Management expects research and development expense to remain fairly flat in the short term and selling, general and administrative expense to remain around its reduced level, with potential increases later to support clinical diagnostic growth.
- Personalis received Medicare coverage for NeXT Dx and is seeking Medicare coverage for NeXT Personal Dx. Reimbursement from other payors remains uncertain.
- The Tempus agreement provides for up to $12 million of market development fees, subject to milestones, and includes commercialization, exclusivity, data-use, and potential revenue-sharing provisions. If the second milestone is not achieved by June 2024, Tempus may withhold installment payments and may terminate or convert the agreement to non-exclusive status.
- The company issued Tempus warrants for up to 9.2 million shares in aggregate. These liability-classified warrants had a $5.3 million fair value at March 31, 2024 and could create future earnings volatility and potential dilution.
- The company completed dissolution of its China subsidiary in February 2024 and reclassified $0.2 million of accumulated foreign currency translation adjustments into other income.
- Personalis is involved in patent litigation against Foresight Diagnostics involving seven asserted MRD patents. The cases were consolidated and stayed in January 2024 while related inter partes review proceedings continue. The filing states that the outcome and financial effect cannot currently be estimated.
- Material risks include continued losses and cash burn, customer concentration, lower Natera pricing and dependence on minimum volumes, uncertain VA MVP renewals, reimbursement and Medicare coverage risk, regulatory changes for laboratory-developed tests, including the FDA’s May 2024 final rule, reliance on Illumina and other suppliers, facility and cybersecurity risks, intellectual-property litigation, and potential need for additional capital.
Most Important Facts for Investors to Verify
- Whether the company can reduce operating cash burn below the Q1 2024 level of $20.4 million while maintaining growth and clinical-development activities.
- The sustainability and pricing of Natera revenue, including the impact of the reduced-cost exome offering and the expiration of minimum volume commitments after 2024.
- The timing and value of future VA MVP task orders and renewals, and the company’s ability to recognize the remaining $5.9 million of task orders.
- Progress toward Medicare and commercial-payor reimbursement for NeXT Dx and NeXT Personal Dx.
- Achievement of the remaining Tempus clinical milestones, future warrant remeasurement gains or losses, and any resulting share dilution.
- The effect and compliance cost of the FDA’s evolving LDT regulatory framework, including potential premarket approval requirements.
- Cash runway, future ATM or other financing activity, and dilution risk; $48.5 million remained available under the ATM facility at March 31, 2024.
- Developments in the Foresight patent litigation and USPTO inter partes review proceedings.